Class
The incretin drugs are this index's approved anchor: peptide analogues of gut hormones with trial programs in the tens of thousands of participants and weight outcomes no other class approaches. They are also where 2026's supply-side changes cut hardest, as the FDA moved to end the mass compounding that grew up during the shortages.
The class question for a reader is no longer whether these drugs work; it is which molecule, at which dose, through which lawful channel.
Molecules in this class
The records are at semaglutide and tirzepatide; the approved page states where compounded copies now stand.